ป้ายกำกับ: alzheimer’s

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

By: Hansa

On: พฤษภาคม 10, 2022

In: JCN Newswire

TOKYO and CAMBRIDGE, Mass., Maอ่านต่อไป

Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting

By: Hansa

On: มีนาคม 11, 2022

In: JCN Newswire

TOKYO, Mar 11, 2022 – (Jอ่านต่อไป

Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM

By: Hansa

On: มกราคม 28, 2022

In: JCN Newswire

Cambridge, MA, Jan 28, 2022 &#อ่านต่อไป

Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

By: Hansa

On: มกราคม 19, 2022

In: JCN Newswire

TOKYO, Jan 19, 2022 – (Jอ่านต่อไป

Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

By: Hansa

On: พฤศจิกายน 12, 2021

In: JCN Newswire

TOKYO, Nov 12, 2021 – (Jอ่านต่อไป

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference

By: Hansa

On: พฤศจิกายน 12, 2021

In: JCN Newswire

TOKYO and CAMBRIDGE, Mass., Noอ่านต่อไป

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease

By: Hansa

On: พฤศจิกายน 9, 2021

In: JCN Newswire

TOKYO, Nov 9, 2021 – (JCอ่านต่อไป

Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study

By: Hansa

On: พฤศจิกายน 4, 2021

In: JCN Newswire

TOKYO, Nov 4, 2021 – (JCอ่านต่อไป

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

By: Hansa

On: กรกฎาคม 30, 2021

In: JCN Newswire

TOKYO, Jul 30, 2021 – (Jอ่านต่อไป

Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

By: Hansa

On: กรกฎาคม 27, 2021

In: JCN Newswire

TOKYO, Jul 27, 2021 – (Jอ่านต่อไป

Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer’s Disease and Dementia at AAIC 2021

By: Hansa

On: กรกฎาคม 21, 2021

In: JCN Newswire

TOKYO, Jul 21, 2021 – (Jอ่านต่อไป

Biogen and Eisai launch initiatives to help patients with Alzheimer’s disease access ADUHELM

By: Hansa

On: มิถุนายน 8, 2021

In: JCN Newswire

Cambridge, MA, Jun 8, 2021 &#8อ่านต่อไป

FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

By: Hansa

On: มิถุนายน 8, 2021

In: JCN Newswire

TOKYO, Jun 8, 2021 – (JCอ่านต่อไป

Notice Regarding Biogen’s Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer’s Disease

By: Hansa

On: เมษายน 23, 2021

In: JCN Newswire

TOKYO, Apr 23, 2021 – (Jอ่านต่อไป

Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease

By: Hansa

On: เมษายน 20, 2021

In: JCN Newswire

TOKYO, Apr 20, 2021 – (Jอ่านต่อไป

Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer’s Disease by Dian-Tu

By: Hansa

On: มีนาคม 16, 2021

In: JCN Newswire

TOKYO, Mar 16, 2021 – (Jอ่านต่อไป

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer’s Disease and Dementia at the 15th International Conference on Alzheimer’s and Parkinson’s Disease

By: Hansa

On: มีนาคม 5, 2021

In: JCN Newswire

TOKYO, Mar 5, 2021 – (JCอ่านต่อไป